At this time, posts about Enzychem Lifesciences are rapidly increasing on portals and stock communities, while foreign investors are tentatively recorded to have sold a net 5,858 shares today. Enzychem Lifesciences is known as a global new drug development and active pharmaceutical ingredient company.
As of 11:31 AM on the 13th, Enzychem Lifesciences' stock price is 111,800 KRW, up 0.36% from the previous day, with a trading volume of 89,598 shares, which is about 40.57% of the 5-day average trading volume. On October 5th, Enzychem Lifesciences was a market issue with the news of being selected as the CRO for the Phase 2 clinical trial of COVID-19, leading to a strong performance.
In addition to Enzychem Lifesciences, posts from investors are also rapidly increasing regarding YG PLUS (037270), Humax Holdings (028080), and Asia Economy (127710).
※Source: AI Investment Assistant AI Lassi
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
